Study: Gene variant affects response to bowel cancer drugs

10/23/2008 | Bloomberg · Yahoo!

Advanced colon cancer patients with a mutation in the BRAF gene do not respond to ImClone Systems' Erbitux and Amgen's Vectibix, Italian researchers reported. The finding comes after earlier studies showed that another gene called KRAS can help identify patients who are most likely to benefit from both drugs.

View Full Article in:

Bloomberg · Yahoo!

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Behavioral Health Operations
Meridian Health Plan
Detroit, MI
Medical Director
PacificSource
Bend, OR
Clinical Appeals RN
MJHS
Brooklyn, NY
Director of Clinical Operations
Meridian Health Plan
Detroit, MI
Sr. Director, Regulatory Compliance Intelligence and Outreach
Johnson & Johnson
New Brunswick, NJ